[Six cases of pulmonary MALT lymphoma: a heterogeneous therapeutic management]

Rev Pneumol Clin. 2011 Jun;67(3):174-8. doi: 10.1016/j.pneumo.2010.05.004. Epub 2011 Feb 2.
[Article in French]

Abstract

Pulmonary mucosa-associated lymphoid tissue lymphomas (PMALT) account for around 1% of lymphomas. Clinical and radiological presentations, and the treatment of six PMALT were collected from 1993 to 2008. All patients received chemotherapy before disease progression. Two patients had a lobectomy and one received thoracic radiotherapy. In 2008, all the patients were alive and three were in remission. A "watch and wait" strategy is widely accepted for stable, asymptomatic patients and patients with low tumour mass. Surgery may be proposed for symptomatic patients who have localised PMALT. When a chemotherapy treatment is to be suggested, chlorambucil-based chemotherapy is preferred. There may be room for rituximab alone or in combination, but this remains to be precisely defined. Several larger studies are currently ongoing to assess the role of monoclonal antibodies and chemotherapy in MALT lymphomas. Subgroup analysis should help us to define the optimal treatment for PMALT.

Publication types

  • English Abstract

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant
  • Chlorambucil / administration & dosage
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphoma, B-Cell, Marginal Zone / drug therapy
  • Lymphoma, B-Cell, Marginal Zone / pathology
  • Lymphoma, B-Cell, Marginal Zone / radiotherapy
  • Lymphoma, B-Cell, Marginal Zone / surgery
  • Lymphoma, B-Cell, Marginal Zone / therapy*
  • Male
  • Middle Aged
  • Pneumonectomy*
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Rituximab
  • Treatment Outcome
  • Watchful Waiting*

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Chlorambucil
  • Rituximab